Bullfrog AI Holdings, Inc.
As of Oct 22, 2026, Bullfrog AI Holdings is in Stage 1, the basing phase, now in its first week (since Oct 16, 2026). It closed at $0.49, 70.7% below its 52-week high and below its 200-day average, which is falling.
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BFRG early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BFRG among Health Information Services32nd of 41 by relative strength
All 41 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | AMWL | Stage 2 · wk 25 | 97 | +7.4% |
| 2 | HNGE | Stage 2 · wk 20 | 96 | +19.1% |
| 3 | BTSG | Stage 3 · wk 8 | 94 | +9.1% |
| 4 | NRC | Stage 3 · wk 4 | 93 | −0.1% |
| 5 | SOPH | Stage 2 · wk 24 | 91 | −12.7% |
| 6 | HTFL | Stage 2 · wk 10 | 87 | +17.0% |
| 7 | HSTM | Stage 2 · wk 17 | 77 | +20.3% |
| 8 | OMCL | Stage 4 · wk 10 | 70 | +12.5% |
| …32 | BFRG | Stage 1 · wk 1 | 17 | −48.1% |
Bullfrog AI Holdings: quick answers
What stage is Bullfrog AI Holdings in?
As of Oct 22, 2026, Bullfrog AI Holdings (BFRG) is in Stage 1, the basing phase. It entered Stage 1 on Oct 16, 2026 and is in its first week there. What the four stages mean
Is Bullfrog AI Holdings in an uptrend?
Not yet. Bullfrog AI Holdings is in Stage 1, a base that can come before an uptrend. It trades 25.5% below its 200-day average, which is falling.
How far is Bullfrog AI Holdings from its 52-week high?
Bullfrog AI Holdings closed at $0.49 on Oct 22, 2026, 70.7% below its 52-week high of $1.68. Its 52-week low is $0.43.
How has Bullfrog AI Holdings performed over the past year?
As of Oct 22, 2026, Bullfrog AI Holdings is down 64.0% over the past year and down 44.0% so far in 2026.
Which sector and industry is Bullfrog AI Holdings in?
Bullfrog AI Holdings is in the Health Information Services industry, part of the Health Care sector.
About this companyHealth Care· Health Information Services
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole, which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.